Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trialZhigong Wei(Sichuan University), Xingchen Peng(Sichuan University)Nature CommunicationsOctober 7, 202510.1038/s41467-025-63978-yCited by 1SaveCiteExport RISWatch citationsRelated PapersSKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway|Cell Death and Disease|2014|27